You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK2 inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

Recruiting
  • Chronic Hand Dermatitis
  • Rochester, New York
    UR Medicine Dermatology College Town
Aug 9, 2022

Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)

Not yet recruiting
  • Myelofibrosis
  • Moderate Thrombocytopenia
  • (no location specified)
Jul 31, 2023

Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood

Not yet recruiting
  • Severe Aplastic Anemia
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

Not yet recruiting
  • Vitiligo
  • Effect of Drug
  • JAK-2 inhibitor
  • Topical corticosteroid
  • (no location specified)
Mar 19, 2022

Arteritis, Giant Cell Trial in Rochester (Baricitinib)

Completed
Has Results
  • Arteritis, Giant Cell
  • Rochester, Minnesota
    Mayo Clinic
Apr 7, 2022

Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)

Active, not recruiting
  • Chronic Graft vs Host Disease
  • Chronic Graft-Versus-Host Disease
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 29, 2022

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Myelofibrosis Trial in Belgium, Netherlands (Pacritinib)

Active, not recruiting
  • Myelofibrosis
  • Antwerpen, Belgium
  • +11 more
Aug 19, 2022

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)

Recruiting
  • Idiopathic Inflammatory Myopathies
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
May 19, 2022

BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

Recruiting
  • BCR-JAK2 Fusion Protein Expression
  • +11 more
  • Palo Alto, California
  • +3 more
Oct 5, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 18, 2022

Myelofibrosis Trial in Paris (Ruxolotinib)

Completed
  • Myelofibrosis
  • Paris, France
    ROBIN
Jul 26, 2022

Rheumatoid Arthritis Trial (Baricitinib 4 MG, Placebo)

Not yet recruiting
  • Rheumatoid Arthritis
  • Baricitinib 4 MG
  • Placebo
  • (no location specified)
Jul 27, 2023

Active Non-anterior Non-infectious Uveitis Trial (Baricitinib 4 MG)

Not yet recruiting
  • Active Non-anterior Non-infectious Uveitis
  • Baricitinib 4 MG
  • (no location specified)
Dec 7, 2022

Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)

Recruiting
  • Acneiform Eruptions
  • Cream containing JAK Inhibitor
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Jun 20, 2022

Myelomonocytic Leukemia Trial in United States (Ruxolitinib)

Completed
Has Results
  • Myelomonocytic Leukemia
  • Tampa, Florida
  • +5 more
Sep 9, 2022

Lupus Nephritis Trial in Assiut (Anti JAK1,2)

Active, not recruiting
  • Lupus Nephritis
  • Anti JAK1,2
  • Assiut, Assuit, Egypt
    Manal Hassanien
Jun 21, 2022

Hemophagocytic Lymphohistiocytoses, Cytokine Storm Trial in Hangzhou (Dexamethasone, Etoposide, Ruxolitinib)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytoses
  • Cytokine Storm
  • Hangzhou, Zhejiang, China
    The Children's Hospital of Zhejiang University School of Medicin
Aug 4, 2022

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Recruiting
  • Rheumatoid Arthritis
  • Upadacitinib <15 MG [Rinvoq]
  • Montpellier, France
    CHU de Montpellier
Jan 12, 2022

Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Itacitinib (INCB039110)
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jul 14, 2022

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
Has Results
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 21, 2022